A Phase II Uncontrolled Study of BAY 73-4506 in Previously Untreated Patients With Metastatic or Unresectable Renal Cell Cancer ( RCC)
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 13 Apr 2017
At a glance
- Drugs Regorafenib (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- Acronyms DAST
- Sponsors Bayer
- 28 Sep 2016 Planned End Date changed from 1 Jan 2017 to 1 Jan 2019.
- 27 Nov 2015 Planned End Date changed from 1 Jan 2016 to 1 Jan 2017, according to ClinicalTrials.gov record.
- 18 Feb 2015 Planned End Date changed from 1 Jan 2015 to 1 Jan 2016 as reported by ClinicalTrials.gov record.